What is Lovenox studying for pregnant women at high risk of blood clots?

This clinical trial is studying how giving Lovenox three times a day affects blood clot prevention in pregnant women who need anticoagulant treatment. Researchers want to see if splitting the dose into three parts keeps blood levels steadier than the usual two doses, which may help reduce clot risk during pregnancy.

Who may be eligible for this pregnancy clinical trial?

Women 18 years or older who are pregnant with a single baby and require therapeutic low molecular weight heparin may be eligible. Women with multiple pregnancies or allergies to enoxaparin are excluded. Please review eligibility criteria for more details.

Is there any cost to participate in this pregnancy clinical trial?

Study-related care, including the study drug and all visits, is provided at no cost. Personal travel expenses may vary and are not guaranteed to be covered.

Actively Recruiting

Phase 4

Age: 18Years +

FEMALE

Healthy Volunteers

ID04861103

Study of Three Times Daily Lovenox Use in Pregnant Women to Prevent Blood Clots

Led by University of California, Irvine · Updated on 2025-10-29

Participants Needed

Research Sites

30 weeks

Total Duration

AI-Summary

What this Trial Is About

Pregnancy increases the risk of developing blood clots by nearly five times, which can be dangerous for both mother and baby. Researchers are studying whether giving the medication Lovenox three times a day instead of the usual twice daily can help maintain more consistent blood levels and potentially reduce this risk. This study focuses on pregnant women who need therapeutic low molecular weight heparin to prevent clots during pregnancy. Participants in this study will receive Lovenox split into three doses per day for five days. The researchers will measure Factor Xa levels, an indicator of how well the medication is working, four hours after injection. This dosing schedule is being tested because changes in blood volume and kidney function during pregnancy may affect how the medication is processed. During the study, women will have their blood tested to check Factor Xa levels after each Lovenox injection. The study team will monitor these levels to understand how three times daily dosing affects medication consistency. Participation includes regular visits over the treatment period, and the research aims to gather detailed information on the medications anticoagulation profile in pregnant women.

CONDITIONS

Brief Title

Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)

Who Can Participate

Age: 18Years +

FEMALE

Healthy Volunteers

Eligibility Criteria

You may qualify if you...

Nulliparous or multiparous women with single intrauterine pregnancies who require therapeutic low molecular weight heparin during their pregnancy.
Participants must be age 18 or older.

You will not qualify if you...

Women with multiples.
Women less than age 18
History of Heparin Induced Thrombocytopenia (HIT)
Allergy to enoxaparin

Research Team

Lizette Spears

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here